Abstract:Genetic variation in the lysosomal and transmembrane protein 106B (TMEM106B) modifies risk for a diverse range of neurodegenerative disorders, especially frontotemporal lobar degeneration (FTLD) with progranulin (PGRN) haplo-insufficiency, although the molecular mechanisms involved are not yet understood. Through advances in cryo-electron microscopy (cryo-EM), homotypic aggregates of the C-Terminal domain of TMEM106B (TMEM CT) were discovered as a previously unidentified cytosolic proteinopathy in the brains of FTLD, Alzheimers disease, progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB) patients. While it remains unknown what role TMEM CT aggregation plays in neuronal loss, its presence across a range of aging related dementia disorders indicates involvement in multi-proteinopathy driven neurodegeneration. To determine the TMEM CT aggregation propensity and neurodegenerative potential, we characterized a novel transgenic C. elegans model expressing the human TMEM CT fragment constituting the fibrillar core seen in FTLD cases. We found that pan-neuronal expression of human TMEM CT in C. elegans causes neuronal dysfunction as evidenced by behavioral analysis. Cytosolic aggregation of TMEM CT proteins accompanied the behavioral dysfunction driving neurodegeneration, as illustrated by loss of GABAergic neurons. To investigate the molecular mechanisms driving TMEM106B proteinopathy, we explored the impact of PGRN loss on the neurodegenerative effect of TMEM CT expression. To this end, we generated TMEM CT expressing C. elegans with loss of pgrn-1, the C. elegans ortholog of human PGRN. Neither full nor partial loss of pgrn-1 altered the motor phenotype of our TMEM CT model suggesting TMEM CT aggregation occurs downstream of PGRN loss of function. We also tested the ability of genetic suppressors of tauopathy to rescue TMEM CT pathology. We found that genetic knockout of spop-1, sut-2, and sut-6 resulted in weak to no rescue of proteinopathy phenotypes, indicating that the mechanistic drivers of TMEM106B proteinopathy may be distinct from tauopathy. Taken together, our data demonstrate that TMEM CT aggregation can kill neurons. Further, expression of TMEM CT in C. elegans neurons provides a useful model for the functional characterization of TMEM106B proteinopathy in neurodegenerative disease.

Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice

Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease

TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy

Physiological and pathological functions of TMEM106B in neurodegenerative diseases

TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy.

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function

TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia

Lysosomal TMEM106B interacts with galactosylceramidase to regulate myelin lipid metabolism

Association of TMEM106B with Cortical APOE Gene Expression in Neurodegenerative Conditions

TMEM59 Haploinsufficiency Ameliorates the Pathology and Cognitive Impairment in the 5xFAD Mouse Model of Alzheimer's Disease

Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging

Tracing TMEM106B Fibril Deposition in Aging and Parkinson’s Disease with Dementia Brains

TFEB-vacuolar ATPase Signaling Regulates Lysosomal Function and Microglial Activation in Tauopathy.

TFEB Regulates Lysosomal Exocytosis of Tau and Its Loss of Function Exacerbates Tau Pathology and Spreading

The TMEM106B FTLD-protective Variant, Rs1990621, is Also Associated with Increased Neuronal Proportion.

TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury

TMEM16F regulates pathologic α‐synuclein secretion and spread in cellular and mouse models of Parkinson's disease

Depletion of TDP-43 exacerbates tauopathy-dependent brain atrophy by sensitizing vulnerable neurons to caspase 3-mediated endoproteolysis of tau in a mouse model of Multiple Etiology Dementia

Newly identified transmembrane protein 106B amyloid fibrils in the human brain: pathogens or by-products?